The LUTONIX® drug-coated balloon: A novel drug delivery technology for the treatment of vascular disease

Advanced Drug Delivery Reviews

Volumn 112, Issue , 2017, Pages 78-87

  Schorn, Ian ^a   Malinoff, Harrison ^a   Anderson, Steven ^a   Lecy, Cyal ^a   Wang, Jeffrey ^a   Giorgianni, Joseph ^a   Papandreou, George ^a  

^a C R BARD INC   (United States)

Author keywords

Angioplasty; Coating; Paclitaxel; Peripheral arterial disease; Peripheral catheterization; Sustained drug delivery

Indexed keywords

BALLOONS; CATHETERS; COATINGS; DIAGNOSIS; DRUG DOSAGE; PATIENT TREATMENT;

ANGIOPLASTY; COMBINATION PRODUCTS; DRUG DELIVERY TECHNOLOGIES; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PERIPHERAL CATHETERIZATION; SUPERFICIAL FEMORAL ARTERIES; THERAPEUTIC APPLICATION;

DRUG PRODUCTS;

PACLITAXEL; POLYSORBATE; SORBITOL; BIOCOMPATIBLE COATED MATERIAL;

BALLOON CATHETER; CLINICAL EFFECTIVENESS; DEVICE APPROVAL; DEVICE SAFETY; DISEASE REGISTRY; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; HUMAN; MATERIAL COATING; OUTCOME ASSESSMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PRODUCT DEVELOPMENT; REVIEW; TISSUE LEVEL; TREATMENT INDICATION; VASCULAR DISEASE; ANIMAL; FEMORAL ARTERY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PROCEDURES; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE;

ANGIOPLASTY, BALLOON; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; FEMORAL ARTERY; HUMANS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES;

EID: 85020056604     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2017.05.015     Document Type: Review

References (54)

1. Mozaffarian, D., et al. Heart disease and stroke statistics- 2016 update. Circulation 133 (2016), e38–e360.
2. Fowkes, F.G.R., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systemic review and analysis. Lancet 382:9901 (2013), 1329–1340.
3. Zeller, T., Current state of endovascular treatment of femoro-popliteal artery disease. Vasc. Med. 12:3 (2007), 223–234.
4. Levy, P.J., Epidemiology and pathophysiology of peripheral arterial disease. Clin. Cornerstone 4:5 (2002), 1–15.
5. Rocha-Singh, K., et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter. Cardiovasc. Interv. 69:6 (2007), 910–919.
6. Dormandy, J.A., Management of peripheral arterial disease TASC working group. TransAtlantic inter-society consensus (TASC). J. Vasc. Surg. 31 (2000), S1–S296.
7. Johnston, K.W., et al. Femoral and politeal arteries: reanalysis of results of balloon angioplasty. Radiology 183:3 (1992), 767–771.
8. Kandzari, D.E., et al. Final 5-year outcomes from the endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc. Interv. 6:5 (2013), 504–512.
9. Holmes, D.R., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:5 (2004), 634–640.
10. Ellis, S.G., et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial. JACC Cardiovasc. Interv. 2:12 (2009), 1248–1259.
11. Dake, M., et al. Paclitaxel-eluting stents shown superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ. Cardiovasc. Interv. 4:5 (2011), 495–504.
12. Klein, A.J., et al. Quantitative assessment of the conformational change in the femoropoliteal artery with leg movement. Catheter. Cardiovasc. Interv. 74:5 (2009), 787–798.
13. Duda, S.H., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Circulation 106 (2002), 1505–1509.
14. Duda, S.H., et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease; the SIROCCO II trial. J. Vasc. Interv. Radiol. 16:3 (2005), 331–338.
15. Scheinert, D., et al. Prevalence and clinical impact of stent fractures after femoropoliteal stenting. J. Am. Coll. Cardiol. 45:2 (2005), 312–315.
16. Waksman, R., et al. Drug-eluting balloon: the comeback kid?. Circ. Cardiovasc. Interv. 2:4 (2009), 352–358.
17. Klugherz, B., et al. Sustained intramural retention and regional redistribution following local vascular delivery of Polylactic-Coglycolic acid and liposomal nanoparticulate formulations containing Probucol. J. Cardiovasc. Pharmacol. Ther. 4:3 (1999), 167–174.
18. Baumbach, A., et al. Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter. Cardiovasc. Interv. 47:1 (1999), 102–106.
19. Cremers, B., et al. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin. Res. Cardiol. 98:5 (2009), 325–330.
20. Scheller, B., et al. Contrast media as carriers for local drug delivery. Eur. Heart J. 24:15 (2003), 1462–1467.
21. Scheller, B., et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355 (2006), 2113–2124.
22. Gray, W.A., et al. Drug-coated balloons for the prevention of vascular restenosis. Circulation 121 (2010), 2672–2680.
23. Potkin, B.N., et al. Effects of coronary angioplasty on atherosclerotic plaques and relation of plaque composition and arterial size to outcome. Am. J. Cardiol. 62:1 (1988), 41–50.
24. Schwartz, R.S., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 19:2 (1992), 267–274.
25. Costa, M.A., et al. Molecular basis of restenosis and drug-eluting stents. Circulation 111:17 (2005), 2257–2273.
26. Forrester, J.S., et al. A paradigm for restenosis based on cell biology: clues for the development of new preventative therapies. J. Am. Coll. Cardiol. 17:3 (1991), 758–769.
27. Axel, D.I., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:2 (1997), 636–645.
28. Kamath, K.R., et al. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv. Drug Deliv. Rev. 58:3 (2006), 412–436.
29. Sollott, S.J., Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95:4 (1995), 1869–1876.
30. Gongora, C.A., et al. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. J. Am. Coll. Cardiol. Intv. 8:8 (2015), 1115–1123.
31. Kelsch, B., et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Investig. Radiol. 46:4 (2011), 255–263.
32. Milewski, K., et al. Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. J. Am. Coll. Cardiol. Intv. 5:10 (2012), 1081–1088.
33. Yazdani, S.K., et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter. Cardiovasc. Interv. 83:1 (2014), 132–140.
34. Scheller, B., et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:7 (2004), 810–814.
35. Yahagi, K., et al. Safety of drug-coated balloons: insights from preclinical studies. Endovasc. Today, 2015, 11–15 (August supplement).
36. Kolodgie, F.D., et al. Comparison of particulate embolization after femoral artery treatment with IN.PACT admiral versus Lutonix 035 paclitaxel-coated balloons in healthy swine. J. Vasc. Interv. Radiol. 27:11 (2016), 1676–1685.
37. Wang, J., et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anti-Cancer Drugs 14:1 (2003), 13–19.
38. Zorger, N., et al. Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on the morphologic results. J. Vasc. Interv. Radiol. 13:4 (2002), 355–359.
39. Zeller, T., Optimizing Outcomes with DCB use: Tips and Tricks. 2015, Transcatheter Cardiovascular Therapeutics (TCT).
40. Clark, C., Exposure risks with cytotoxic drugs. Hosp. Pharm. Eur. 49 (2010), 15–16.
41. Ward, C., et al. TCT-289 detection of paclitaxel contamination resulting from the simulated clinical use of drug coated balloon catheters. J. Am. Coll. Cardiol., 64(11), 2014, B83.
42. Virmani, R., A Study of Downstream Events of Two Leading DCBs on the Market. 2016, Leipzig Interventional Course (LINC).
43. Scheinert, D., et al. The LEVANT 1 trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc. Interv. 7:1 (2014), 10–19.
44. Jaff, M.R., et al. Drug coated balloons to improve Femoropopliteal artery patency: rationale and design of the LEVANT 2 trial. Am. Heart J. 169:4 (2015), 479–485.
45. Rosenfield, K., et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N. Engl. J. Med. 373:2 (2015), 145–153.
46. Scheinert, D., et al. German center sub-group analysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of Femoropopliteal occlusive disease. J. Endovasc. Ther. 23:3 (2016), 409–416.
47. Scheinert, D., Latest Insights from the LEVANT 2 Study and sub-Group Analysis. 2016, LINC.
48. Lutonix® 035 Drug Coated Balloon PTA Catheter, Instructions for use bard peripheral vascular. ([Online] [Cited: March 3, 2017.]) http://www.bardpv.com/wp-content/uploads/2016/06/DW5159-01-Rev06-IFU-Lutonix-035-Model-9004-US.pdf.
49. Thieme, M., et al. Worldwide experience with Lutonix DCB in global SFA registry: 24-month follow-up. JACC Cardiovasc. Interv., 2016 (submitted for publication).
50. Metzger, D.C., et al. TCT-17 the Lutonix global DCB registry real world patients with complex Femero-popliteal lesions – 24 month outcome. J. Am. Coll. Cardiol. 68:18 (2016), B7–B8 (Supplement).
51. Lutonix® DCB vs. standard balloon angioplasty for treatment of below the knee (BTK) arteries. www.clinicaltrials.gov ([Online] NCT01870401).
52. Lutonix® drug coated balloon vs. standard balloon angioplasty for treatment of Femoropopliteal in-stent restenosis (SFA-ISR). www.clinicaltrials.gov ([Online] NCT02063672).
53. Study Company Lutonix® AV Drug Coated Balloon vs. Standard Balloon for Treatment of Dysfunctional AV Fistulae. ([Online] NCT02440022).
54. Guidance for Industry, Coronary Drug-Eluting Stents — Nonclinical and Clinical Studies. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health (CDRH), Center for Drug Evaluation and Research (CDER). March 2008.